Evaluation of therapeutic effect in metastatic castration-resistant prostatic cancer using FDG-PET/CT

Evaluation of therapeutic effect in metastatic castration-resistant prostatic cancer using FDG-PET/CT - FDG-PET/CT in metastatic castration-resistant prostatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024237

Enrollment

Registered

2016-12-19

Start date

2017-01-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic castration-resistant prostatic cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Patients who are diagnosed to have metastatic castration-resistant prostate cancer in the Department of Urology, Kyoto University Hospital. 2. Patients who have metastatic lesions confirmed by bone scintigraphy and/or X-ray CT. 3. Patients who are going to be treated with abiraterone or enzalutamide. 4. Patients aged over 20 years old. 5. Patients who can read and understand the document of this study and have the ability to judge on the participation to this study.

Exclusion criteria

Exclusion criteria: 1. Patients who have problems in communication. 2. Patients with deteriorated general condition. 3. Patients with severe hepatic/renal dysfunction. 4. Patients with uncontrollable diabetes mellitus. 5. Patients who received FDG-PET/CT within 3 weeks of informed consent. 6. Patients to whom physicians judged inappropriate for this study.

Design outcomes

Primary

Measure	Time frame
1. FDG uptake parameters in metastatic lesions obtained before and 12 weeks after the start of treatment 2. Number of bone metastases detected by bone scintigraphy performed before and 12 weeks after the start of treatment 3. Size of metastatic lesion detected by X-ray CT performed before and 12 weeks after the start of treatment 4. Serum PSA levels before and 12 weeks after the start of treatment	—

Measure

Time frame

1. FDG uptake parameters in metastatic lesions obtained before and 12 weeks after the start of treatment 2. Number of bone metastases detected by bone scintigraphy performed before and 12 weeks after the start of treatment 3. Size of metastatic lesion detected by X-ray CT performed before and 12 weeks after the start of treatment 4. Serum PSA levels before and 12 weeks after the start of treatment

—

Secondary

Measure	Time frame
Prognostic information of mid-term follow-up patients	—

Countries

Japan

Contacts

Public ContactTsuneo Saga

Kyoto University Hospital Department of Diagnostic Radiology

saga@kuhp.kyoto-u.ac.jp075-751-3760

Outcome results